Trial Outcomes & Findings for Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers (NCT NCT05109442)

NCT ID: NCT05109442

Last Updated: 2025-08-20

Results Overview

The number of patients with dose limiting toxicities (DLTs) in the first cycle, as assessed by the National Cancer Institute Common Technology Criteria for Adverse Events (CTCAE) v5.0

• Recruitment status: TERMINATED
• Study phase: PHASE1/PHASE2
• Target enrollment: 112 participants
• Primary outcome timeframe: During cycle 1 (each cycle has 28 days)
• Results posted on: 2025-08-20

Participant Flow

Participant milestones

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic, EGFR-WT expressing NSCLC whose disease has progressed after having received ≥1 prior lines of therapy for advanced disease. Patients must have received at least a platinum-based doublet in combination with an anti--programmed cell death protein 1 (PD1)/programmed death-ligand 1 (PD-L1) antibody or must have received an anti-PD1/PD-L1 antibody prior to or after a platinum-based doublet. Patients with a known actionable driver mutation (other than EGFR mutation) must have received an approved targeted treatment for the respective mutation. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the standard of care (SOC) is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with locally advanced, unresectable, or metastatic gastric or GEJ adenocarcinoma refractory to or, intolerant of, standard therapy. Patients must have received ≥1 prior chemotherapy regimen including a platinum and fluoropyrimidine doublet. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Overall Study STARTED	4	6	49	12	11	30
Overall Study COMPLETED	0	0	0	0	0	0
Overall Study NOT COMPLETED	4	6	49	12	11	30

Reasons for withdrawal

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic, EGFR-WT expressing NSCLC whose disease has progressed after having received ≥1 prior lines of therapy for advanced disease. Patients must have received at least a platinum-based doublet in combination with an anti--programmed cell death protein 1 (PD1)/programmed death-ligand 1 (PD-L1) antibody or must have received an anti-PD1/PD-L1 antibody prior to or after a platinum-based doublet. Patients with a known actionable driver mutation (other than EGFR mutation) must have received an approved targeted treatment for the respective mutation. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the standard of care (SOC) is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with locally advanced, unresectable, or metastatic gastric or GEJ adenocarcinoma refractory to or, intolerant of, standard therapy. Patients must have received ≥1 prior chemotherapy regimen including a platinum and fluoropyrimidine doublet. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Overall Study Withdrawal by Subject	0	0	1	0	0	0
Overall Study Adverse Event	0	1	5	0	0	2
Overall Study Death	0	0	4	0	0	1
Overall Study Physician Decision	1	0	1	0	0	2
Overall Study Other than listed	0	0	9	2	0	8
Overall Study Lack of Efficacy	3	5	29	10	11	17

Baseline Characteristics

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Baseline characteristics by cohort

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=4 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=6 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=49 Participants Patients aged 18 years or older with advanced or metastatic, EGFR-WT expressing NSCLC whose disease has progressed after having received ≥1 prior lines of therapy for advanced disease. Patients must have received at least a platinum-based doublet in combination with an anti--programmed cell death protein 1 (PD1)/programmed death-ligand 1 (PD-L1) antibody or must have received an anti-PD1/PD-L1 antibody prior to or after a platinum-based doublet. Patients with a known actionable driver mutation (other than EGFR mutation) must have received an approved targeted treatment for the respective mutation. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the standard of care (SOC) is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg n=12 Participants Patients aged 18 years or older with locally advanced, unresectable, or metastatic gastric or GEJ adenocarcinoma refractory to or, intolerant of, standard therapy. Patients must have received ≥1 prior chemotherapy regimen including a platinum and fluoropyrimidine doublet. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=11 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=30 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Total n=112 Participants Total of all reporting groups
Age, Continuous	60.8 years STANDARD_DEVIATION 10.3 • n=5 Participants	55.0 years STANDARD_DEVIATION 20.2 • n=7 Participants	64.9 years STANDARD_DEVIATION 9.1 • n=5 Participants	59.2 years STANDARD_DEVIATION 7.5 • n=4 Participants	58.3 years STANDARD_DEVIATION 12.1 • n=21 Participants	64.2 years STANDARD_DEVIATION 9.5 • n=8 Participants	62.8 years STANDARD_DEVIATION 10.4 • n=8 Participants
Sex: Female, Male Female	4 Participants n=5 Participants	4 Participants n=7 Participants	13 Participants n=5 Participants	3 Participants n=4 Participants	7 Participants n=21 Participants	20 Participants n=8 Participants	51 Participants n=8 Participants
Sex: Female, Male Male	0 Participants n=5 Participants	2 Participants n=7 Participants	36 Participants n=5 Participants	9 Participants n=4 Participants	4 Participants n=21 Participants	10 Participants n=8 Participants	61 Participants n=8 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	4 Participants n=5 Participants	6 Participants n=7 Participants	45 Participants n=5 Participants	12 Participants n=4 Participants	10 Participants n=21 Participants	30 Participants n=8 Participants	107 Participants n=8 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	4 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	5 Participants n=8 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	18 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	18 Participants n=8 Participants	37 Participants n=8 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants
Race (NIH/OMB) White	4 Participants n=5 Participants	6 Participants n=7 Participants	30 Participants n=5 Participants	12 Participants n=4 Participants	9 Participants n=21 Participants	12 Participants n=8 Participants	73 Participants n=8 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants
Region of Enrollment South Korea	0 participants n=5 Participants	0 participants n=7 Participants	18 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	17 participants n=8 Participants	35 participants n=8 Participants
Region of Enrollment United States	0 participants n=5 Participants	1 participants n=7 Participants	1 participants n=5 Participants	0 participants n=4 Participants	1 participants n=21 Participants	2 participants n=8 Participants	5 participants n=8 Participants
Region of Enrollment Poland	0 participants n=5 Participants	0 participants n=7 Participants	16 participants n=5 Participants	0 participants n=4 Participants	3 participants n=21 Participants	4 participants n=8 Participants	23 participants n=8 Participants
Region of Enrollment United Kingdom	0 participants n=5 Participants	1 participants n=7 Participants	4 participants n=5 Participants	1 participants n=4 Participants	0 participants n=21 Participants	1 participants n=8 Participants	7 participants n=8 Participants
Region of Enrollment Spain	4 participants n=5 Participants	4 participants n=7 Participants	10 participants n=5 Participants	11 participants n=4 Participants	7 participants n=21 Participants	6 participants n=8 Participants	42 participants n=8 Participants

PRIMARY outcome

Timeframe: During cycle 1 (each cycle has 28 days)

Population: Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab

The number of patients with dose limiting toxicities (DLTs) in the first cycle, as assessed by the National Cancer Institute Common Technology Criteria for Adverse Events (CTCAE) v5.0

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=4 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=6 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Phase 1: Incidence of Dose Limiting Toxicities (DLTs) During Cycle 1	0 Participants	1 Participants	—	—	—	—

PRIMARY outcome

Timeframe: Tumor assessments were conducted during last week of cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter (each cycle has 28 days), up to approximately 97 weeks.

Population: Full Analysis Set (FAS): All patients who completed the Safety Lead-in phase and received any amount of any component of the combination treatments AFM24 and atezolizumab

Tumor assessment by RECIST v1.1 by investigator. Best overall response was used to define the Overall Response Rate (CR or PR). Best overall response is CR or PR if a CR or PR assessed at least 42 days after Cycle 1 Day 1 was confirmed by subsequent tumor assessment at least 4 weeks later.

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=43 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=12 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=11 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=28 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Phase 2a: Overall Response Rate (Complete Response [CR] or Partial Response [PR])	8 Participants	1 Participants	1 Participants	4 Participants	—	—

SECONDARY outcome

Timeframe: From first drug administration up to 30 (non-serious TEAEs) or 56 (serious TEAEs) days after last dose AFM24, until start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approx. 35 (phase 1) and 105 weeks (phase 2a).

Population: Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab

Number of patients with treatment-emergent adverse events (TEAEs) non-serious or serious

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=4 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=6 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=49 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=12 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=11 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=30 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Incidence of Patients With TEAEs	4 Participants	6 Participants	49 Participants	11 Participants	11 Participants	30 Participants

SECONDARY outcome

Timeframe: From first drug administration up to 56 days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a).

Population: Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab

Number of patients with treatment-emergent serious adverse events (serious TEAEs)

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=4 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=6 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=49 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=12 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=11 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=30 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Incidence of Patients With SAEs	2 Participants	3 Participants	30 Participants	6 Participants	7 Participants	15 Participants

SECONDARY outcome

Timeframe: During cycle 1 (each cycle has 28 days)

Population: All subjects who received at least one adequately documented dose of study drug and had sufficient PK measurements at Cycle 1 Day 22 analysed in central lab.

Maximum plasma concentration (Cmax) on Cycle 1 Day 22

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=3 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=4 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=35 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=11 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=8 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=20 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Pharmacokinetics (PK) of AFM24	73700 ng/mL Standard Deviation 25400	269000 ng/mL Standard Deviation 61400	207000 ng/mL Standard Deviation 78100	207000 ng/mL Standard Deviation 73400	175000 ng/mL Standard Deviation 77200	250000 ng/mL Standard Deviation 106000

SECONDARY outcome

Timeframe: During cycle 1 (each cycle has 28 days)

Population: All subjects who received at least one adequately documented dose of study drug and had sufficient PK measurements at Cycle 1 Day 22 analysed in central lab.

Minimum plasma concentration (Cmin) Corresponding to Ctrough levels at the end of the dosing interval at Cycle 1 Day 22

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=3 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=4 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=36 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=12 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=7 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=19 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Pharmacokinetics (PK) of AFM24	16700 ng/mL Standard Deviation 12500	105000 ng/mL Standard Deviation 37200	56300 ng/mL Standard Deviation 48500	73700 ng/mL Standard Deviation 40900	71900 ng/mL Standard Deviation 62500	93700 ng/mL Standard Deviation 51600

SECONDARY outcome

Timeframe: During cycle 1 (each cycle has 28 days)

Population: All subjects who received at least one adequately documented dose of study drug and had sufficient PK measurements at Cycle 1 Day 22 analysed in central lab.

Area under the concentration-time curve over the dose interval (AUCtau) on Cycle 1 Day 22

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=3 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=3 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=31 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=11 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=7 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=15 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Pharmacokinetics (PK) of AFM24	5760 hours*microgram /milliLiter Standard Deviation 919	27900 hours*microgram /milliLiter Standard Deviation 9780	19800 hours*microgram /milliLiter Standard Deviation 9660	21500 hours*microgram /milliLiter Standard Deviation 8620	20500 hours*microgram /milliLiter Standard Deviation 11400	28600 hours*microgram /milliLiter Standard Deviation 11900

SECONDARY outcome

Timeframe: During cycle 1 (each cycle has 28 days)

Population: All subjects who received at least one adequately documented dose of study drug and had sufficient PK measurements at Cycle 1 Day 22 analysed in central lab.

Time to Cmax (Tmax) on Cycle 1 Day 22

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=3 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=4 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=35 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=11 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=8 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=20 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Pharmacokinetics (PK) of AFM24	3.15 h Standard Deviation 0.03	3.15 h Standard Deviation 0.13	9.78 h Standard Deviation 17.9	27.9 h Standard Deviation 24.5	8.63 h Standard Deviation 15.8	10.6 h Standard Deviation 17.4

SECONDARY outcome

Timeframe: Ph 1 within 2h prior to: each drug intake (Cycle 1), 1st + 3rd drug intake (Cycle 2 onwards) and at EOT, up to 27 weeks. Ph 2a within 2h prior to: 1st drug intake (Cycle 1 and Cycle 3 onwards), 1st + 3rd drug intake (Cycle 2) and at EOT, up to 97 weeks.

Population: Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab

Measurement of ADAs before and during treatment with AFM24 in combination with atezolizumab Patients with at least one ADA-positive result at baseline or post-baseline counted as developing anti-drug antibodies (ADAs) against AFM24

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=4 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=6 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=49 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=12 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=11 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=30 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Frequency of Patients Developing Anti-drug Antibodies (ADAs) Against AFM24	1 Participants	2 Participants	12 Participants	2 Participants	3 Participants	7 Participants

SECONDARY outcome

Timeframe: Tumor assessments were conducted during last week of cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter (each cycle has 28 days), up to approximately 27 weeks.

Population: Full Analysis Set (FAS): All patients who completed the Safety Lead-in phase and received any amount of any component of the combination treatments AFM24 and atezolizumab

Tumor assessment by RECIST v1.1 by investigator. Best overall response was used to define the Overall Response Rate (CR or PR). Best overall response is CR or PR if a CR or PR assessed at least 42 days after Cycle 1 Day 1 was confirmed by subsequent tumor assessment at least 4 weeks later.

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=3 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=6 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Phase 1: Overall Response Rate (Complete Response [CR] or Partial Response [PR])	1 Participants	0 Participants	—	—	—	—

SECONDARY outcome

Timeframe: From the first treatment received until the first progression disease assessed by investigator or death.

Population: Full Analysis Set (FAS): All patients who completed the Safety Lead-in phase and received any amount of any component of the combination treatments AFM24 and atezolizumab

Progression-Free Survival (PFS) was defined as (date of first progression - date of first study drug injection)/30.4375. Patients without progression or death were censored. Tumor assessment by RECIST v1.1 by investigator.

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=43 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=12 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=11 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=28 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Phase 2a: Progression-free Survival	3.75 Months Interval 1.91 to 5.85	1.94 Months Interval 1.48 to 8.71	1.91 Months Interval 0.99 to 2.53	3.71 Months Interval 1.87 to 7.46	—	—

SECONDARY outcome

Timeframe: From the date of first response (unconfirmed) until progression disease assessed by investigator or death.

Population: All patients from Full Analysis Set (FAS) (=completed the Safety Lead-in phase and received any amount of any component of the combination treatments AFM24 and atezolizumab) who had a response by RECIST v1.1 by investigator assessment.

Duration of Response (DOR) was defined as (date of first progression or death - date of first response (unconfirmed))/30.4375. Patients without response were excluded from the analysis. Patients without progression or death were censored. Tumor assessment by RECIST v1.1 by investigator.

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=8 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=1 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=1 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=4 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Phase 2a: Duration of Response	9.20 Months Interval 3.71 to Not enough events to calculate the data.	NA Months Not enough events to calculate the data.	3.71 Months Not enough events to calculate the data.	11.07 Months Interval 6.54 to Not enough events to calculate the data.	—	—

SECONDARY outcome

Timeframe: Tumor assessments were conducted during last week of cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter (each cycle has 28 days), up to approximately 97 weeks.

Population: Full Analysis Set (FAS): All patients who completed the Safety Lead-in phase and received any amount of any component of the combination treatments AFM24 and atezolizumab

Tumor assessment by RECIST v1.1 by investigator. Best overall response was used to define the Clinical benefit rate (CR or PR or SD ≥24 weeks). Best overall response is CR or PR if a CR or PR assessed at least 42 days after Cycle 1 Day 1 was confirmed by subsequent tumor assessment at least 4 weeks later. Best overall response is SD if SD or unconfirmed CR or unconfirmed PR at least 42 days after C1D1. Best overall response SD counts for Clinical benefit rate if SD ongoing for at least 24 weeks.

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=43 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=12 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=11 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=28 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Phase 2a: Clinical Benefit Rate (CR or PR [Any Duration] or Stable Disease Equal or > 24 Weeks)	11 Participants	2 Participants	1 Participants	8 Participants	—	—

SECONDARY outcome

Timeframe: Tumor assessments were conducted during last week of cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter (each cycle has 28 days), up to approximately 97 weeks.

Population: Full Analysis Set (FAS): All patients who completed the Safety Lead-in phase and received any amount of any component of the combination treatments AFM24 and atezolizumab

Tumor assessment by RECIST v1.1 by investigator. Best overall response was used to define the Disease Control Rate (CR or PR or SD). Best overall response is CR or PR if a CR or PR assessed at least 42 days after Cycle 1 Day 1 was confirmed by subsequent tumor assessment at least 4 weeks later. Best overall response is SD if SD or unconfirmed CR or unconfirmed PR at least 42 days after C1D1.

Outcome measures

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=43 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=12 Participants Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=11 Participants Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=28 Participants Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Phase 2a: Disease Control Rate (DCR) (Complete Response [CR] or Partial Response [PR] or Stable Disease [SD])	27 Participants	5 Participants	2 Participants	14 Participants	—	—

Adverse Events

Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg

Serious events: 2 serious events

Other events: 4 other events

Deaths: 3 deaths

Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg

Serious events: 3 serious events

Other events: 6 other events

Deaths: 5 deaths

Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg

Serious events: 30 serious events

Other events: 48 other events

Deaths: 21 deaths

Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg

Serious events: 6 serious events

Other events: 11 other events

Deaths: 9 deaths

Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg

Serious events: 7 serious events

Other events: 11 other events

Deaths: 9 deaths

Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg

Serious events: 15 serious events

Other events: 29 other events

Deaths: 9 deaths

Serious adverse events

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=4 participants at risk Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=6 participants at risk Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=49 participants at risk Patients aged 18 years or older with advanced or metastatic, EGFR-WT expressing NSCLC whose disease has progressed after having received ≥1 prior lines of therapy for advanced disease. Patients must have received at least a platinum-based doublet in combination with an anti--programmed cell death protein 1 (PD1)/programmed death-ligand 1 (PD-L1) antibody or must have received an anti-PD1/PD-L1 antibody prior to or after a platinum-based doublet. Patients with a known actionable driver mutation (other than EGFR mutation) must have received an approved targeted treatment for the respective mutation. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the standard of care (SOC) is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg n=12 participants at risk Patients aged 18 years or older with locally advanced, unresectable, or metastatic gastric or GEJ adenocarcinoma refractory to or, intolerant of, standard therapy. Patients must have received ≥1 prior chemotherapy regimen including a platinum and fluoropyrimidine doublet. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=11 participants at risk Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=30 participants at risk Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Reproductive system and breast disorders Vaginal prolapse	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Pneumonia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.2% 5/49 • Number of events 6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations COVID-19	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Pneumocystis jirovecii pneumonia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Biliary sepsis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations COVID-19 pneumonia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Endocarditis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Escherichia bacteraemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Escherichia sepsis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Lung abscess	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Peritonitis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Sepsis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Urinary tract infection	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.2% 4/49 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Organising pneumonia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Sputum increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.7% 2/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Injury, poisoning and procedural complications Fall	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Injury, poisoning and procedural complications Spinal fracture	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Dysphagia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 2/12 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Abdominal pain upper	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Constipation	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Diarrhoea	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Gastrointestinal disorder	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Large intestinal obstruction	25.0% 1/4 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.0% 3/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Blood and lymphatic system disorders Neutropenia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Blood and lymphatic system disorders Anaemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Blood and lymphatic system disorders Anaemia of malignant disease	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Cardiac disorders Atrial fibrillation	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Cardiac disorders Cardiac tamponade	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Cardiac disorders Coronary artery disease	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Cardiac disorders Myocardial infarction	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Fatigue	25.0% 1/4 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Hyperthermia malignant	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Multiple organ dysfunction syndrome	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour haemorrhage	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Cerebrovascular accident	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Haemorrhage intracranial	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Seizure	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Subarachnoid haemorrhage	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Alanine aminotransferase increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Aspartate aminotransferase increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Blood bilirubin increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Blood alkaline phosphatase increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Gamma-glutamyltransferase increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Immune system disorders Cytokine release syndrome	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Hypophagia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Vascular disorders Pelvic venous thrombosis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Vascular disorders Superior vena cava syndrome	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Hepatobiliary disorders Jaundice cholestatic	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).

Other adverse events

Measure	Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg n=4 participants at risk Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 160 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg n=6 participants at risk Patients aged 18 years or older with documented histologically or cytologically confirmed select advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=49 participants at risk Patients aged 18 years or older with advanced or metastatic, EGFR-WT expressing NSCLC whose disease has progressed after having received ≥1 prior lines of therapy for advanced disease. Patients must have received at least a platinum-based doublet in combination with an anti--programmed cell death protein 1 (PD1)/programmed death-ligand 1 (PD-L1) antibody or must have received an anti-PD1/PD-L1 antibody prior to or after a platinum-based doublet. Patients with a known actionable driver mutation (other than EGFR mutation) must have received an approved targeted treatment for the respective mutation. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the standard of care (SOC) is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg n=12 participants at risk Patients aged 18 years or older with locally advanced, unresectable, or metastatic gastric or GEJ adenocarcinoma refractory to or, intolerant of, standard therapy. Patients must have received ≥1 prior chemotherapy regimen including a platinum and fluoropyrimidine doublet. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg n=11 participants at risk Patients aged 18 years or older with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype; Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma. Patients must have been treated with at least 1 previous line of an approved, SOC therapy for the respective disease type or, in the opinion of the Investigator, available SOC is not appropriate. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.	Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg n=30 participants at risk Patients aged 18 years or older with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥1 prior lines of therapy for advanced disease including ≥1 prior tyrosine kinase inhibitor (TKI) approved for EGFR mutated NSCLC, such as gefitinib, erlotinib, afatinib, dacomitinib or osimertinib. Patients who were treated with a 1st or 2nd generation TKI in 1st line and developed a documented T790M mutation must have received a TKI targeting this mutation such as osimertinib or lazertinib to be eligible. Patients must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulating free tumor DNA. The patients should also have received a second line of treatment if approved and available, or they may be enrolled in the study if in the opinion of the Investigator it is in the patient's best interest, or the SOC is not appropriate. The patients received AFM24 480 mg i.v. qw + atezolizumab 840 mg i.v. q2w in 28-day cycles. AFM24 on Day 1, Day 8, Day 15, and Day 22 (a dose could be given as split day dosing over two days) + atezolizumab on Day 1 and Day 15.
Gastrointestinal disorders Nausea	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	50.0% 3/6 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.2% 5/49 • Number of events 8 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Dyspepsia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	18.2% 2/11 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Abdominal pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	33.3% 2/6 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Rash erythematous	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Injury, poisoning and procedural complications Infusion related reaction	50.0% 2/4 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	83.3% 5/6 • Number of events 6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	51.0% 25/49 • Number of events 31 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	75.0% 9/12 • Number of events 11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	72.7% 8/11 • Number of events 9 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	63.3% 19/30 • Number of events 20 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Injury, poisoning and procedural complications Medication error	25.0% 1/4 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Injury, poisoning and procedural complications Fall	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Injury, poisoning and procedural complications Lumbar vertebral fracture	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Injury, poisoning and procedural complications Procedural pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Injury, poisoning and procedural complications Radiation mucositis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Injury, poisoning and procedural complications Tendon rupture	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Injury, poisoning and procedural complications Thermal burn	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Asthenia	25.0% 1/4 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	14.3% 7/49 • Number of events 9 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	41.7% 5/12 • Number of events 9 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	72.7% 8/11 • Number of events 13 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 5/30 • Number of events 6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Fatigue	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	33.3% 2/6 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.3% 8/49 • Number of events 9 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	13.3% 4/30 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Pyrexia	25.0% 1/4 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.2% 5/49 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	18.2% 2/11 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.0% 3/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Chest pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Chills	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	18.2% 2/11 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Oedema peripheral	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 2/12 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Catheter site pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Exercise tolerance decreased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Malaise	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Oedema	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Soft tissue inflammation	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
General disorders Swelling	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Diarrhoea	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	25.0% 3/12 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	45.5% 5/11 • Number of events 7 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.0% 3/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Constipation	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	18.2% 2/11 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	13.3% 4/30 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Vomiting	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	33.3% 2/6 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	18.2% 2/11 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Ascites	75.0% 3/4 • Number of events 8 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	33.3% 2/6 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 2/12 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Dry mouth	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Abdominal distension	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Abdominal pain upper	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Dysphagia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Gingival pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Stomatitis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Tongue ulceration	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Toothache	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Alanine aminotransferase increased	25.0% 1/4 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	50.0% 3/6 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	20.4% 10/49 • Number of events 15 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	25.0% 3/12 • Number of events 6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	20.0% 6/30 • Number of events 15 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Aspartate aminotransferase increased	25.0% 1/4 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	50.0% 3/6 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.3% 8/49 • Number of events 12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	25.0% 3/12 • Number of events 6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	20.0% 6/30 • Number of events 25 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Neutrophil count decreased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 5/30 • Number of events 13 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Amylase increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.7% 2/30 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Gamma-glutamyltransferase increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.0% 3/30 • Number of events 6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Lipase increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Weight decreased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Hepatic enzyme increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Blood creatinine increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Bilirubin conjugated increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Blood alkaline phosphatase increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Blood bilirubin increased	25.0% 1/4 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Blood lactate dehydrogenase increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations C-reactive protein increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Electrocardiogram QT prolonged	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Heart rate decreased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Lymphocyte count decreased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Platelet count decreased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Waist circumference increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations Weight increased	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Investigations White blood cells urine positive	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Decreased appetite	25.0% 1/4 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	33.3% 2/6 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.2% 4/49 • Number of events 7 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	36.4% 4/11 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.0% 3/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.2% 4/49 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.0% 3/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.2% 4/49 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Diabetes mellitus	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.7% 2/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Metabolism and nutrition disorders Vitamin D deficiency	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Upper respiratory tract infection	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.0% 3/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Herpes zoster	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.0% 3/30 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Paronychia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Rash pustular	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations COVID-19	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Nasopharyngitis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Pneumonia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Urinary tract infection	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.7% 2/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Viral infection	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Bacteraemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Bronchitis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Candida infection	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Influenza	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Otitis media	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Pneumocystis jirovecii pneumonia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Respiratory tract infection	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Sinusitis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Infections and infestations Skin infection	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Cough	25.0% 1/4 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.2% 5/49 • Number of events 6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 5/30 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Dyspnoea	25.0% 1/4 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.2% 4/49 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.0% 3/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Catarrh	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Pleuritic pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Blood and lymphatic system disorders Neutropenia	50.0% 2/4 • Number of events 6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.2% 4/49 • Number of events 8 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 16 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 5/30 • Number of events 8 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Blood and lymphatic system disorders Anaemia	50.0% 2/4 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 8 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	27.3% 3/11 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.7% 2/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Blood and lymphatic system disorders Lymphopenia	75.0% 3/4 • Number of events 25 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	33.3% 2/6 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	18.2% 2/11 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Blood and lymphatic system disorders Leukopenia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	18.2% 2/11 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Blood and lymphatic system disorders Thrombocytopenia	25.0% 1/4 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	18.2% 2/11 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Blood and lymphatic system disorders Increased tendency to bruise	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Blood and lymphatic system disorders Leukocytosis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	36.4% 4/11 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	13.3% 4/30 • Number of events 5 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.2% 4/49 • Number of events 7 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 10 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.7% 2/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.7% 2/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	18.2% 2/11 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.0% 3/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Rash	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	33.3% 2/6 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 2/12 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.7% 2/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Eczema	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Nail disorder	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Acne	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Butterfly rash	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Erythema	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Macule	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Perioral dermatitis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Photosensitivity reaction	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Rash macular	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Rosacea	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Skin lesion	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Skin and subcutaneous tissue disorders Skin maceration	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Headache	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.2% 4/49 • Number of events 11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.7% 2/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Paraesthesia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.0% 3/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Dizziness	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.7% 2/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Taste disorder	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Aphasia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Restless legs syndrome	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Seizure	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Syncope	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Nervous system disorders Vocal cord paralysis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.7% 2/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	6.1% 3/49 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Vascular disorders Hypertension	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Vascular disorders Haematoma	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	16.7% 1/6 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Vascular disorders Hypotension	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Vascular disorders Peripheral artery thrombosis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Vascular disorders Peripheral venous disease	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Vascular disorders Superior vena cava syndrome	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Vascular disorders Vena cava thrombosis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Psychiatric disorders Insomnia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	8.3% 1/12 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	10.0% 3/30 • Number of events 3 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Psychiatric disorders Anxiety	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Cardiac disorders Atrial fibrillation	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	4.1% 2/49 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Cardiac disorders Angina unstable	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Endocrine disorders Adrenal insufficiency	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 2 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Endocrine disorders Hyperthyroidism	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Endocrine disorders Hypothyroidism	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Hepatobiliary disorders Hepatitis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Hepatobiliary disorders Jaundice	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Hepatobiliary disorders Jaundice cholestatic	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	9.1% 1/11 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Renal and urinary disorders Haematuria	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Renal and urinary disorders Nephrolithiasis	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Eye disorders Dry eye	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Eye disorders Ocular hyperaemia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Ear and labyrinth disorders Ear pain	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Immune system disorders Contrast media allergy	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/49 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	3.3% 1/30 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).
Reproductive system and breast disorders Benign prostatic hyperplasia	0.00% 0/4 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/6 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	2.0% 1/49 • Number of events 1 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/12 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/11 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).	0.00% 0/30 • From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a). Safety Analysis Set (SAS): All patients who received at least any amount of AFM24 or atezolizumab. Reported in the tables below are the TEAEs (treatment-emergent Adverse Events).

Additional Information

Clinical Operations

Affimed GmbH

Phone: +49 621 56003-0

Email: trials@affimed.com

Results disclosure agreements

• Principal investigator is a sponsor employee The sponsor has the right to review communications for 90 days prior to public release (whereby the sponsor may ask to consider modifications to ensure necessary protection of sponsor's IP). Any publication shall be not made before the first multi-centre publication if the study is a part of a multi-centred clinical trial. Also, if a publication concerns the analyses of data from a multi-centred clinical trial, the communication shall make reference to the relevant multi-centre publication
• Publication restrictions are in place

Restriction type: OTHER